Immunotherapy Brings Three-Year Survival in Rare, Usually Fatal Lung Vascular Cancer Syndrome
A Japanese case report describes more than three years of progression-free survival in pulmonary tumour thrombotic microangiopathy after prompt nivolumab ...
